Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
29.23 USD | -2.18% | +1.88% | -7.49% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 13.42 for the current year and 7.67 for next year, earnings multiples are highly attractive compared with competitors.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.49% | 1.7B | C- | ||
+42.69% | 749B | C+ | ||
+38.52% | 605B | B | ||
-6.87% | 351B | C+ | ||
+18.74% | 328B | B- | ||
+6.76% | 292B | C+ | ||
+11.19% | 216B | B- | ||
-2.70% | 214B | A+ | ||
+2.64% | 167B | C+ | ||
+6.72% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HRMY Stock
- Ratings Harmony Biosciences Holdings, Inc.